Apexigen Inc Quick Ratio (APGN) starting from the second quarter 2023 to second quarter 2022, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Apexigen Inc   (NASDAQ: APGN)

Apexigen Inc 's Quick Ratio

APGN's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Current Liabilities decreased faster than Apexigen Inc 's Cash & cash equivalent, this led to improvement in Apexigen Inc 's Quick Ratio to 1.07, Quick Ratio remained below Apexigen Inc average.

Within Major Pharmaceutical Preparations industry 439 other companies have achieved higher Quick Ratio than Apexigen Inc in second quarter 2023. While Quick Ratio total ranking has improved so far during the Q2 2023 to 2135, from total ranking in the first quarter 2023 at 2187.

Explain Quick Ratio?
How much Cash & cash equivalents APGN´s has?
What are APGN´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

APGN Quick Ratio (Jun 30 2023)
Q2		 (Mar 31 2023)
Q1		 (Dec 31 2022)
Q4		 (Sep 30 2022)
Q3		 (Jun 30 2022)
Q2
Y / Y Current Liabilities Change 81.54 % 455.05 % -26.56 % 6998.45 % 4165.63 %
Y / Y Cash & cash equivalent Change 12072.27 % 13541.23 % -28.34 % 7431.37 % -78.14 %
Quick Ratio MRQ 1.07 0.88 1.57 1.98 0.02
APGN's Total Ranking # 2135 # 2187 # 659 # 1444 # 4150
Seq. Current Liabilities Change -39.51 % 35.05 % 2.55 % 116.7 % 84.95 %
Seq. Cash & cash equivalent Change -26.4 % -24.22 % -18.74 % 26758.52 % -17.52 %



Quick Ratio second quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 440
Healthcare Sector # 803
Overall Market # 2135


Quick Ratio Statistics
High Average Low
5.09 1.53 0
(Mar 31 2021)   (Dec 31 2020)




Financial Statements
Apexigen Inc 's Current Liabilities $ 9 Millions Visit APGN's Balance sheet
Apexigen Inc 's Cash & cash equivalent $ 9 Millions Visit APGN's Balance sheet
Source of APGN's Sales Visit APGN's Sales by Geography


Cumulative Apexigen Inc 's Quick Ratio

APGN's Quick Ratio for the trailling 12 Months

APGN Quick Ratio

 (Jun 30 2023)
12 Months		 (Mar 31 2023)
12 Months		 (Dec 31 2022)
12 Months		 (Sep 30 2022)
12 Months		 (Jun 30 2022)
12 Months
Y / Y Current Liabilities TTM Growth 100.25 % 131.73 % 91.46 % 2028.49 % 1508.36 %
Y / Y Cash & cash equivalent TTM Growth 149.38 % 108.08 % 53.7 % 4123.19 % 2985.67 %
Quick Ratio TTM 1.34 1.24 1.32 1.37 1.08
Total Ranking TTM # 4113 # 1708 # 4125 # 1918 # 4239
Seq. Current Liabilities TTM Growth 9.72 % 41.49 % -11.94 % 46.47 % 26.97 %
Seq. Cash & cash equivalent TTM Growth 18.48 % 33.57 % -15 % 85.39 % -1.14 %

Quick ratio ranking by company, industry and sector >> Back to APGN Financial Strength Comparisons >> Go to Compare APGN Quick Ratio to its Competitors

On the trailing twelve months basis APGN Cash & cash equivalent more than doubled by 12072.27 % in Q2 2023 year on year, faster than Current Liabilities, this led to increase in in Apexigen Inc 's Quick Ratio to 1.34, above APGN average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 549 other companies have achieved higher Quick Ratio than Apexigen Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2023 from 1708 to 4113.

Explain Quick Ratio?
How much Cash & cash equivalents APGN´s has?
What are APGN´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 550
Healthcare Sector # 1105
Within the Market # 4113


trailing twelve months Quick Ratio Statistics
High Average Low
2.39 0.92 0.09
(Dec 31 2021)   (Jun 30 2022)




Companies with similar Quick Ratio in the quarter ending Jun 30 2023, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2023 MRQ Cash & cash equivalentJun 30 2023 MRQ Current Liabilities
Seres Therapeutics Inc   2.95 $ 229.520  Millions$ 77.898  Millions
Decibel Therapeutics Inc   2.95 $ 78.300  Millions$ 26.578  Millions
Hookipa Pharma inc   2.93 $ 135.587  Millions$ 46.245  Millions
Monopar Therapeutics Inc   2.88 $ 7.215  Millions$ 2.502  Millions
Precigen Inc   2.87 $ 88.434  Millions$ 30.773  Millions
Gt Biopharma Inc   2.87 $ 17.973  Millions$ 6.261  Millions
Elicio Therapeutics Inc   2.85 $ 21.682  Millions$ 7.597  Millions
Galera Therapeutics Inc   2.85 $ 38.755  Millions$ 13.622  Millions
Nextcure Inc   2.82 $ 22.019  Millions$ 7.820  Millions
Maia Biotechnology Inc   2.79 $ 9.146  Millions$ 3.273  Millions
Horizon Therapeutics Public Limited Company  2.69 $ 2,469.414  Millions$ 917.681  Millions
23andme Holding Co  2.64 $ 314.351  Millions$ 118.909  Millions
Reata Pharmaceuticals Inc   2.64 $ 330.214  Millions$ 125.093  Millions
Adial Pharmaceuticals Inc   2.64 $ 1.218  Millions$ 0.462  Millions
Insmed Inc  2.62 $ 917.768  Millions$ 349.673  Millions
Neximmune Inc   2.60 $ 16.281  Millions$ 6.268  Millions
Genprex Inc   2.58 $ 9.956  Millions$ 3.860  Millions
Alnylam Pharmaceuticals Inc   2.57 $ 2,030.251  Millions$ 788.639  Millions
Universe Pharmaceuticals Inc  2.55 $ 19.871  Millions$ 7.783  Millions
Mereo Biopharma Group Plc  2.54 $ 56.321  Millions$ 22.187  Millions
Gyre Therapeutics Inc   2.48 $ 6.923  Millions$ 2.793  Millions
Tempest Therapeutics Inc   2.44 $ 17.604  Millions$ 7.224  Millions
Beone Medicines Ltd   2.43 $ 3,420.061  Millions$ 1,405.109  Millions
Neubase Therapeutics inc   2.43 $ 14.873  Millions$ 6.123  Millions
Bio path Holdings inc   2.42 $ 3.444  Millions$ 1.426  Millions
Macrogenics Inc   2.41 $ 108.758  Millions$ 45.155  Millions
Tvardi Therapeutics Inc   2.38 $ 58.249  Millions$ 24.475  Millions
Omeros Corporation  2.38 $ 341.283  Millions$ 143.538  Millions
Vistagen Therapeutics Inc   2.38 $ 9.622  Millions$ 4.049  Millions
Vaxxinity Inc   2.35 $ 55.848  Millions$ 23.780  Millions

Date modified: 2026-08-29T17:43:38+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.